Goserelin
Primary Ovarian Failure
Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Beni-Suef University
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04536467CT.gov Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Ovarian Failure
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Goserelin (this asset) | Beni-Suef University | P2 | CCC · 52 |
| Bushen Culuan Decoction | Xiyuan Hospital of China Academy of Chinese Medical Sciences | P2 | CCC |
| Human Chorionic Gonadotropin | Lebanese University | P1/2 | CCC |
Other indications for Goserelin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P4 | BB · 70 |
| Breast Cancer | — | P4 | BB · 70 |
| Prostate Adenocarcinoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Goserelin in Primary Ovarian Failure. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/goserelin-primary-ovarian-failure
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →